U2AF1Q157R neoantigen-specific TCR-T cells

U2AF1Q157R neoantigen-specific TCR-T cells are a type of **adoptive cell therapy** in which a patient's own T cells are genetically engineered to express a T cell receptor (TCR) that specifically recognizes the mutant U2AF1 Q157R neoantigen, a tumor-specific mutation most commonly identified in myeloid malignancies such as myelodysplastic syndromes and acute myeloid leukemia. Upon reinfusion, these TCR-T cells can recognize and destroy cancer cells expressing the U2AF1 Q157R mutant peptide presented by human leukocyte antigen (HLA) molecules. The expected mechanism is highly targeted antitumor immunity, with a goal of eradicating malignant clones harboring the U2AF1 Q157R mutation while sparing normal tissue. This is a personalized cell therapy and is not a standardized small molecule or monoclonal antibody. The modality is cell therapy—specifically, T cell receptor engineered T cell therapy.